About Us

Mylan’s history, mission and values tell the story of who we are as a company. We began more than 50 years ago as a pharmaceutical distributor, providing products to customers in rural communities.

Today, we’re one of the world’s leading pharmaceutical companies, with a significant and growing presence in India. We sell our products in approximately 165 countries and territories. What hasn’t changed is our dedication to providing access to high quality medicine.

History

Explore more than 50 years of unconventional success.

  1. Mylan founders
    0
    History

    Day 1

    First known as Milan, the company starts doing business in White Sulphur Springs, West Virginia. U.S. Army chums, Milan "Mike" Puskar and Don Panoz flip a coin to see who will name the business and who will be the company’s first president. They start distributing products to doctors and chemists from an old Pontiac Bonneville.
    History
  2. 0
    Mylan FDA approval

    Moves to Morgantown

    We move to Morgantown, West Virginia in 1965 and begin manufacturing various over-the-counter products the next year. Success leads to a decision to switch production to generic pharmaceuticals.

    Mylan FDA approval
  3. Mylan FDA approval
    0
    Mylan Penicillin G

    Our First Medicine

    After receiving approval from the FDA to manufacture our first medicine, Penicillin G, we broaden our product line to include other generic antibiotics as well as analgesics, antihistamines, diuretics and tranquilizers. We market these to large drug companies, drug store chains and mail-order drug providers, all for resale under the customers’ own labels.
    Mylan Penicillin G
  4. 1969: New Partner, New Look
    0

    New Partner, New Look

    Parke-Davis is the first major pharmaceutical company to purchase and privately label Milan products. We also introduce a new logo—the letter “M” formed by three test tubes suggests scientific leadership and teamwork.

  5. 1972: From Milan to Mylan
    0

    From Milan to Mylan

    We change the spelling of Mylan to stand out at the bottom of the list of stocks that begin with the letter "M".

  6. Mylan goes public
    0
    1973: Mylan Going Public

    Going Public

    To fuel expansion, Mylan goes public. By the end of the 1970s, we produce five of the 10 most prescribed generic medicines—all five are antibiotics.

    1973: Mylan Going Public
  7. 0
    1976: New Leadership

    New Leadership

    Mike Puskar, who had left the company, returns as president. He and chairman and CEO Roy McKnight lead Mylan through a period of unprecedented growth.
    1976: New Leadership
  8. Generic Pharmaceutical Industry Association
    0
    1982: GPIA and Hatch-Waxman

    GPIA and Hatch-Waxman

    Mike Puskar helps establish the Generic Pharmaceutical Industry Association, GPIA, to give the industry a voice. During the next few years, GPIA lobbies for the Hatch-Waxman Act, which passes in 1984.
    1982: GPIA and Hatch-Waxman
  9. First-to-Market
    0
    1984: First to Market

    First to Market

    Our first branded product approval, for MAXZIDE® TABLETS (triamterene and hydrocholorothiazide tablets, US), is a first for a generics company.
    1984: First to Market
  10. 1989
    0
    1989: Doing What’s Right, Not What’s Easy

    Doing What’s Right, Not What’s Easy

    We see irregularities in how the Food and Drug Administration (FDA) acts on ANDAs, abbreviated new drug applications. Our investigation helps expose fraudulent practices and corruption in the industry. This results in reform of the FDA’s review procedures for generic drugs and new precautions to help ensure consumer safety.

    1989: Doing What’s Right, Not What’s Easy
  11. Bertek & UDL Labs
    0
    Bertek & UDL Labs

    Diversification

    The market is becoming increasingly competitive as demand for high quality, affordable medication rises.

    • In 1993, we acquire Bertek Inc., an innovator of transdermal medicine systems. Bertek is later renamed Mylan Technologies Inc., or MTI
    • In 1996, Mylan adds unit dose packaging with the acquisition of UDL, the largest pharmaceutical unit dose packaging company in the United States
    • At the same time, generic utilization rises to about 47%, and we continue to capture market share while discontinuing private labeling and growing our own “Mylan” label
    Bertek & UDL Labs
  12. 0
    1993: New CEO

    New CEO

    Mike Puskar becomes chairman and CEO.
    1993: New CEO
  13. Biggest pharma companies
    0
    1995: Another First

    Another First

    We become the most-dispensed line of brand and generic pharmaceuticals in the U.S.

    1995: Another First
  14. Mylan 2002 revenue
    0
    Mylan packaging

    Growing Into the 21st century

    Soon after entering our fifth decade, we declare a turnover of $1 billion.

    Mylan packaging
  15. 0
    Robert J. Coury

    Robert J. Coury

    Robert J. Coury is elected to the board of directors and becomes vice chairman and CEO.
    Robert J. Coury
  16. 0
    2004: Added to S&P 500

    Eleven Billion

    In 2004, Mylan was added to the S&P 500 and shipped eleven billion doses, more than any other pharmaceutical company.
    2004: Added to S&P 500
  17. Generic vs. Brand
    0
    2004-2006: Organic Growth

    Organic Growth

    In the U.S., the Medicare Prescription Drug, Improvement and Modernization Act and an aging Medicare population fuel generic utilization, which reaches 78% by decade’s end. We are ready, having put in place a plan to expand through organic growth and acquisitions from a mid-size company into a global leader.
    2004-2006: Organic Growth
  18. 0
    2006: Setting New standards in health care

    Setting New Standards in Health Care

    Executive Heather Bresch testifies before the U.S. Senate’s Special Committee on Ageing regarding issues that put billions of dollars of consumer healthcare savings at risk.
    2006: Setting New standards in health care
  19. Mylan Global
    0
    Matrix Labs

    Going Global

    We become a global company by acquiring a controlling interest in Matrix Laboratories, a supplier of active pharmaceutical ingredients (API), and by purchasing Merck KGaA’s generics business.

    • Matrix has low-cost manufacturing facilities in India and China and marketing capabilities in Western Europe and Africa. Matrix gives us unprecedented control over our supply chain and expands our dosage forms and therapeutic categories. This includes the addition of antiretroviral medicines for people living with HIV/AIDS
    • Merck KGaA’s generic business sells products in more than 90 countries. Combining forces provides massive global scale, expands our product portfolio and provides entry into new commercial markets
    • With the acquisition of Merck KGaA generic business, we acquire the rights to EpiPen®(epinephrine) Auto-Injector, the world's No. 1 dispensed epinephrine auto-injector*
    • *IMS data, 1987-2012
      Matrix Labs
    • Mylan 2008 revenue
      0
      2008: Continued Growth

      Continued Growth

      We declare a turnover of $5 billion.
      2008: Continued Growth
    • 2009
      0
      2009: Global Leadership

      Global Leadership

      • Mike Puskar retires and Robert J. Coury is named chairman of the board.
      • We launch next-generation EpiPen® Auto-Injector (epinephrine).
      • Our first global product, LANSOPRAZOLE (lansoprazole capsule, delayed release pellets), launches.
      • Lopinavir/Ritonavir, an innovative heat-stable ARV treatment, is created for use certain countries where refrigeration isn't readily available.
      • Robert J. Coury and former President Bill Clinton announce an agreement for better, more affordable treatment for HIV/AIDS patients in the developing world.
      • Mylan is named to the Fortune 500 list.

        *Mylan remained on the list until it reincorporated outside the U.S. in 2015.
      2009: Global Leadership
    • 0
      2010: Bioniche Pharma

      Bioniche Pharma

      Our acquisition of Bioniche Pharma expands our injectable portfolio with products for use in orthopedics, rheumatology, urology and dermatology.
      2010: Bioniche Pharma
    • 0
      Mylan book

      Our First 50 Years

      • Mylan celebrates 50 years of unconventional success.
      • We acquire Pfizer’s respiratory delivery platform.
      Mylan book
    • FDASIA
      0
      GDUFA

      Championing National Policy

      Mylan, led by Heather Bresch, champions the Food and Drug Administration Safety and Innovation Act (FDASIA), which holds both foreign and domestic manufacturers to one global quality standard. The Act includes the Generic Drug User Fee Act (GDUFA). Together, FDASIA and GDUFA aim to speed up access to safe and effective generic medicines while providing more visibility into how medicines and their ingredients are manufactured and shipped around the world.

      Read story >

      GDUFA
    • 0
      Mylan Executives

      Expanding Leadership

      We introduce a new and expanded management structure to help fuel our continued growth and success. Robert J. Coury transitions into the role of executive chairman of the board. Heather Bresch is promoted to CEO and Rajiv Malik is promoted to president.

      Mylan Executives
    • 0
      Mylan India

      Unprecedented Growth

      • We launch commercial operations in India and team up with Pfizer in Japan
      • Mylan is selected as a supplier to India’s National AIDS Control Organization and is named the leading antiretroviral supplier to the South African National Department of Health
      • Nearly 40% of patients receiving treatment in developing countries are using a Mylan product
      Mylan India
    • 0
      Mylan Headquarters

      New Global Centre

      Operations begin at our new Robert J. Coury Global Centre in Pittsburgh, Pennsylvania, a 280,000-square-foot, five-story innovative workspace.

      Mylan Headquarters
    • 0
      Agila

      Ongoing Global Leadership

      • Our antiretroviral portfolio launches in South Africa
      • EpiPen®(epinephrine) Auto-Injector celebrates 25 years as the No. 1 prescribed epinephrine auto-injector in the U.S.*
      • Mylan acquires Agila Specialties creating a global injectables leader
      • *IMS data, 1987-2012
      Agila
    • 0
      Agila

      2015: Better Health for a Better World

      Mylan acquires Abbott's non-U.S. developed markets specialty and branded generics business.

      Agila

    Mylan’s Mission

    At Mylan, we are committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we:
    • Innovate to satisfy unmet needs
    • Make reliability and service excellence a habit
    • Do what’s right, not what’s easy
    • Impact the future through passionate global leadership
    Mylan Mission Mosaic

    Our Values

    Mother and daughter laughing
    Innovation
    We are unconventional, visionary and bold. We “connect the dots” others overlook. We see possibilities and bring them to life. We love to challenge the status quo and introduce new and better ways to help people everywhere enjoy a higher quality of life. Having the courage to be a force for constructive change is in our DNA.

    We see the opportunity to innovate in every challenge
    Integrity
    Doing what's right is sacred to us. We behave responsibly, even when nobody's looking. We set high standards from which we never back down. This uncompromising ethical stance helps to keep our products pure, our workers safe and the environment clean.

    Watch our Integrity at work

    Reliability
    Dependable. Reliable. Call it what you will, we've made it a habit. We strive to be there through thick and thin, rain or shine, delivering on every promise, every time. That's why people around the corner and across the world count on Mylan.

    Seven billion people rely on us

    Service
    We understand that "it's not about us"—it's about helping others—and we believe there's no situation we can't handle. We would do whatever it takes, work ‘round the clock, cross any river and spare no effort—all to meet someone’s need. We wrap our high quality products in high quality service.

    Creating access to HIV/AIDS medications

    Teamwork
    Together, we can run faster, reach higher and achieve more than any one of us can alone. We relish opportunities to collaborate because it’s invigorating, enlightening and powerful. When we join forces and plow through boundaries, we move mountains.

    Meet our leadership team

    Mylan at a Glance

    1961: Year founded in White Sulphur Springs, West Virginia., U.S. 
    ~7 billion: People we work to provide with access to high quality medicine
    ~165: Countries and territories in which our products are sold
    >1,400: Separate products currently being marketed
    1 of 2: Global generics companies with true vertical integration
    ~35,000: Workforce

    Manufacturing capacity

    65 billion oral solid doses
    3,600 kiloliters active pharmaceutical ingredients 
    500 million injectable units
    260 million patches
    15 million semisolid units


    Mylan Fact Sheet